The Thai government and international pharmaceutical companies have failed to reach an agreement in recent talks over compulsory licenses issued by the country for certain medications...Abbott Laboratories recently announced that it has withdrawn applications to sell seven new drugs in Thailand in response to the country's decision to issue a compulsory license for the company's antiretroviral drug Kaletra...Abbott offered to lower Kaletra's cost to $167 per patient monthly, although representatives from the health ministry said that was still too high. Abbott and the ministry agreed to meet for further negotiations...[also refers to Merck]